
Tenpoint Therapeutics is a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the aging eye. Our pipeline includes paradigm-shifting therapeutics for ophthalmic indications with significant unmet medical need, including presbyopia, cataracts, and geographic atrophy.
Our lead product, YUVEZZI™, is the first and only dual-agent eye drop for the treatment of presbyopia in adults and was approved by the FDA on January 28, 2026. Presbyopia, the gradual loss of near vision that typically begins around age 45, affects about two billion people globally and 128 million people in the U.S. YUVEZZI™ is expected to be broadly commercially available in the U.S. in Q2 2026.
The Director of ECP Marketing plays a critical role in executing Tenpoint’s professional marketing strategy and launch readiness plans. Reporting to the Vice President of ECP Marketing and eCommerce, this individual will serve as a key operational lead responsible for translating strategic vision into field-ready programs, sales tools, and omnichannel activations.
The Director will oversee the day-to-day management of ECP marketing execution, lead the development of field and practice integration tools, coordinate omnichannel initiatives, and serve as a key liaison among marketing, sales, and operations. This role will also provide tactical support for Tenpoint’s emerging eCommerce platform, ensuring alignment with field and customer needs.
ECP Marketing Execution
Omnichannel Planning & Delivery
Sales Training & Field Readiness
eCommerce Support & Cross-Functional Collaboration
Experience
This role is primarily a desk-based job requiring the ability to operate a computer and communicate effectively in a remote work environment. The employee may be required to sit for extended periods, engage in video or phone meetings, and use standard office equipment. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of the role. If you need assistance and/or a reasonable accommodation during the interview process, please let our recruiting team know.
We are an Equal Opportunity Employer. Consistent with applicable law, all qualified applicants will receive consideration for employment without regard to race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity, Veteran status, or any other characteristic protected by applicable local laws, regulations and ordinances.
We know our people are the driving force behind the success of our mission and vision. That’s why we offer a competitive benefit package to attract the very best talent to our team and to take care of our employees and their families. Below is a snapshot of our U.S. benefits package for full-time employees.
For more information, visit www.tenpointherapeutics.com and follow us on LinkedIn, X, and Instagram

This page is intended for US audiences only.
Tenpoint Therapeutics Limited is a commercial-ready biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy.
Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that impacts nearly 128 million people in the U.S. Tenpoint Therapeutics has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL PF, has filed the NDA and has received a Prescription Drug User Fee Act (PDUFA) date from the US FDA of January 28, 2026. Tenpoint Therapeutics’ leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster treatments.